Advantages of DNA immunization platform for eliciting mAbs in multiple species

October 19, 2018

New Rochelle, NY, October 19, 2018--Researchers have taken advantage of the benefits of DNA immunization over traditional protein-based immunization to elicit monoclonal antibodies (mAbs) against challenging targets in three species - mouse, rabbit, and human models. They describe their use of DNA immunization as a new mAb development plat-form in an article published in a Special Issue on DNA Vaccines in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Human Gene Therapy website through November 19, 2018.

Shuying Liu, SYL Consulting, Thousand Oaks, CA and Shixia Wang and Shan Lu, University of Massachusetts Medical School, Worcester, MA coauthored the article entitled "Using DNA Immunization to Elicit Monoclonal Antibodies in Mice, Rabbits, and Humans." Shan Lu was Guest Editor of the Special Issue.

The researchers described the multiple advantages of DNA immunization, including the ability to stimulate both innate and adaptive immunity to elicit high levels of antigen-specific antibody responses, to activate multiple pathways of innate immunity, and to-gether with T cells to lead to the development of antigen-specific B cells that can gener-ate high affinity antibody responses.

"The innovative approach described by this team demonstrates the great flexibility and utility of DNA vaccines in the creation of monoclonal antibodies," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "In this context, it represents a particularly precise approach to precision medicine."
-end-
Research reported in this publication was supported by the National Institutes of Health un-der Award Numbers U19AI082676, P01AI082274, and 5R21/R33AI087191. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the Journal

Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly and focused on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Monoclonal Antibodies Articles from Brightsurf:

Rapid method finds potent COVID-19 monoclonal antibody among a trillion possibilities
University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19.

NEJM: clinical trial indicates monoclonal antibody lowered hospitalizations and emergency visits
COVID-19 (coronavirus) patients who were administered a novel antibody had fewer symptoms and were less likely to require hospitalization or emergency medical care than those who did not receive the antibody, according to a new study published in the The New England Journal of Medicine.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

A simple screening process may enhance monoclonal antibody-based drug development
By screening potential monoclonal antibody (mAb)-based drugs solely based on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

X-ray experiments zero in on COVID-19 antibodies
An antibody derived from a SARS survivor in 2003 appears to effectively neutralize the coronavirus that causes COVID-19, opening the door for speedy development of a targeted treatment.

Towards antibodies against COVID-19
The lab of Xavier Saelens (VIB-UGent Center for Medical Biotechnology) announces the isolation and characterization of a unique antibody that can bind to the virus that causes COVID-19 (SARS-CoV-2).

Antibodies from llamas could help in fight against COVID-19
Initial tests of a new candidate antibody treatment for COVID-19 indicate that it blocks viruses that display the SARS-CoV-2 spike protein from infecting cells in culture.

Antibodies could provide new treatment for OCD
Mental health conditions such as obsessive compulsive disorder could be treated in a new way using drugs that target the immune system, research suggests.

Read More: Monoclonal Antibodies News and Monoclonal Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.